首页> 美国卫生研究院文献>Cancers >Chemotherapeutic Drugs Inhibiting Topoisomerase 1 Activity Impede Cytokine-Induced and NF-κB p65-Regulated Gene Expression
【2h】

Chemotherapeutic Drugs Inhibiting Topoisomerase 1 Activity Impede Cytokine-Induced and NF-κB p65-Regulated Gene Expression

机译:抑制拓扑异构酶1活性的化学治疗药物会抑制细胞因子诱导和NF-κBp65调控的基因表达。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Inhibitors of DNA topoisomerase I (TOP1), an enzyme relieving torsional stress of DNA by generating transient single-strand breaks, are clinically used to treat ovarian, small cell lung and cervical cancer. As torsional stress is generated during transcription by progression of RNA polymerase II through the transcribed gene, we tested the effects of camptothecin and of the approved TOP1 inhibitors Topotecan and SN-38 on TNFα-induced gene expression. RNA-seq experiments showed that inhibition of TOP1 but not of TOP2 activity suppressed the vast majority of TNFα-triggered genes. The TOP1 effects were fully reversible and preferentially affected long genes. TNFα stimulation led to inducible recruitment of TOP1 to the gene body of IL8, where its inhibition by camptothecin reduced transcription elongation and also led to altered histone H3 acetylation. Together, these data show that TOP1 inhibitors potently suppress expression of proinflammatory cytokines, a feature that may contribute to the increased infection risk occurring in tumor patients treated with these agents. On the other hand, TOP1 inhibitors could also be considered as a therapeutic option in order to interfere with exaggerated cytokine expression seen in several inflammatory diseases.
机译:DNA拓扑异构酶I(TOP1)的抑制剂是一种通过产生瞬时单链断裂来缓解DNA扭转应力的酶,在临床上用于治疗卵巢癌,小细胞肺癌和宫颈癌。由于转录过程中RNA聚合酶II通过转录的进程在转录过程中产生了扭转应力,因此我们测试了喜树碱以及批准的TOP1抑制剂Topotecan和SN-38对TNFα诱导的基因表达的影响。 RNA-seq实验表明,抑制TOP1而不抑制TOP2活性可以抑制绝大多数TNFα触发的基因。 TOP1效应是完全可逆的,并且优先影响长基因。 TNFα刺激导致可诱导的TOP1募集到IL8的基因体中,喜树碱对TOP1的抑制作用会降低转录伸长率,并导致组蛋白H3乙酰化改变。总之,这些数据表明,TOP1抑制剂有效抑制促炎细胞因子的表达,这一特征可能有助于增加接受这些药物治疗的肿瘤患者发生感染的风险。另一方面,TOP1抑制剂也可被视为一种治疗选择,以干扰几种炎症性疾病中细胞因子的过度表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号